Clinical Trial: Gilenya® capsules (fingolimod, Novartis Pharmaceuticals AG) versus Copaxone® (glatir - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Gilenya® capsules (fingolimod, Novartis Pharmaceuticals AG) versus Copaxone® (glatiramer acetate, Teva Pharmaceutical Industries, Ltd.

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 2550
Medication: Gilenya, Copaxone
Location: AL|AZ|CA|CO|CT|DE|DC|FL|IL|IN|IA|KY|LA|MA|MI|MO|NJ|NY|NC|OH|OK|PA|RI|SC|TN|TX|VA|WA
Contact Information
William.Gunther@ppdi.com

Funding:

Novartis Pharmaceuticals AG

 

Description

A 12-month, randomized, blinded study to compare the effectiveness and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting MS. 

Share